We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-19.64%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$240M
AUM Growth
-$51.7M
Cap. Flow
+$25.2M
Cap. Flow %
10.52%
Top 10 Hldgs %
50.22%
Holding
91
New
10
Increased
29
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$6.75M
2
CGEN icon
Compugen
CGEN
+$4.71M
3
AGTC
Applied Genetic Technologies Corporation
AGTC
+$4.22M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$3.78M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$3.7M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$9.94M
2
CYTK icon
Cytokinetics
CYTK
+$4.44M
3
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
+$3.7M
4
ATRC icon
AtriCure
ATRC
+$2.84M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 91.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASLN
76
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$88K 0.04%
2,152
-790
-27% -$60K
LCTX icon
77
Lineage Cell Therapeutics
LCTX
$278M
$79K 0.03%
95,000
– –
URGN icon
78
UroGen Pharma
URGN
$2.29B
$42K 0.02%
2,369
-1,618
-41% -$43.7K
CYTK icon
79
Cytokinetics
CYTK
$10.4B
– –
-418,727
Closed -$4.44M
INSM icon
80
Insmed
INSM
$28.6B
– –
-30,000
Closed -$716K
SCYX icon
81
SCYNEXIS
SCYX
$52M
– –
-15,093
Closed -$1.1M
TPST icon
82
Tempest Therapeutics
TPST
$14.6M
– –
-664
Closed -$873K
YARW
83
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
– –
-222
Closed -$3.7M
WVE icon
84
Wave Life Sciences
WVE
$1.2B
– –
-36,960
Closed -$296K
EVLO
85
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
– –
-536
Closed -$44K
ADXS
86
DELISTED
Advaxis Inc
ADXS
– –
-350,000
Closed -$300K
TBIO
87
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-179,845
Closed -$1.46M
ACHN
88
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-438,884
Closed -$2.65M
ARQL
89
DELISTED
Arqule Inc
ARQL
– –
-497,762
Closed -$9.94M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, DAFNA Capital Management held 91 positions worth $240M, down 18% from $291M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management deployed $25.2M of net new capital in Q1 2020, opening 10 new positions and adding to 29 existing holdings. Its largest new stake was Compugen: 600,000 shares worth $4.36M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was AtriCure, an estimated $2.84M trimmed.

  • DAFNA Capital Management's largest Q1 2020 buy was Compugen: 600,000 shares worth $4.36M.
  • DAFNA Capital Management added most to Blueprint Medicines in Q1 2020, an estimated $6.75M increase.
  • DAFNA Capital Management's biggest Q1 2020 reduction was AtriCure, cutting an estimated $2.84M.
  • DAFNA Capital Management fully exited Arqule Inc in Q1 2020, selling an estimated $9.94M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $240M portfolio in Q1 2020.
  • DAFNA Capital Management opened 10 new positions and closed 11 in Q1 2020.
  • DAFNA Capital Management's portfolio value fell 18% quarter-over-quarter to $240M.

Based on DAFNA Capital Management's 13F filing for Q1 2020, filed 15 May 2020.